Full history for every metric is available with a Kvantra account
Unity Biotechnology, Inc. (UBX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 5 | 0 | 0 | 0 | 1 |
| Operating profit | $m | -31 | -28 | |||||
| Net profit | $m | -82 | -94 | -61 | -44 | -40 | -26 | -28 |
| EPS reported | $ | -1.54 | -1.62 | |||||
| Operating cashflow per share | $ | -1.24 | -1.24 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.24 | -1.24 | |||||
| Free cash flow | $m | -21 | -22 | |||||
| Net debt | $m | -23 | -13 | |||||
| Book value equity | $m | 6 | - | |||||
| Book value per share | $ | 0.39 | - | |||||
| Number of shares | m | 16.83 | 16.87 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.53 | 0.52 | |||||
| P/S LTM | x | 0.00 | 2.59 | |||||
| P/FCF LTM | x | -0.79 | -0.16 | |||||
| EV/EBITDA LTM | x | -1.29 | 0.36 | |||||
| EV/Sales LTM | x | 0.00 | -7.20 | |||||
| Earnings Yield LTM | % | -158.19% | -771.88% | |||||
| FCF Yield | % | -126.99% | -639.89% | |||||
| Quality | ||||||||
| ROE | % | -400.22% | -148.97% | |||||
| ROIC | % | -96.71% | -96.71% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -30.18% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.89 | -0.97 | |||||
| Net Debt/EBITDA | x | -0.64 | -0.64 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -141.39% | -377.54% | |||||
| Net debt/Equity | x | -3.58 | - | |||||
| Gross debt/equity | x | 3.62 | - | |||||
Company overview
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Unity Biotechnology, Inc. (UBX)
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free